Publications

• Harries, R. L. et al. 2018. Impact of pigment epithelium-derived factor on colorectal cancer in vitro and in vivo. Oncotarget 9 (27), pp.19192-19202. (10.18632/oncotarget.24953)
• Owen, S. et al. 2018. Key factors in breast cancer dissemination and establishment at the bone: past, present and future perspectives. In: Song, E. and Hu, H. eds. Translational Research in Breast Cancer:Biomarker Diagnosis, Targeted Therapies and Approaches to Precision. Vol. 1026, Advances in Experimental Medicine and Biology Singapore: Kluwer. , pp.197-216. (10.1007/978-981-10-6020-5_9)
• Riaz, S. K. et al., 2018. Involvement of hedgehog pathway in early onset, aggressive molecular subtypes and metastatic potential of breast cancer. Cell Communication and Signaling 16 3. (10.1186/s12964-017-0213-y)
• Xie, M. et al. 2018. MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer. Gastric Cancer 21 (1), pp.41-54. (10.1007/s10120-017-0721-x)
• Laprevotte, E. et al., 2017. The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget 8 , pp.113360-113372. (10.18632/oncotarget.23008)
• Ma, S. et al., 2017. Claudin-5 regulates blood-brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis. CNS Neuroscience & Therapeutics 23 (12), pp.947-960. (10.1111/cns.12764)
• Tao, T. et al., 2017. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation. Oncogene 36 , pp.6119-6131. (10.1038/onc.2017.199)
• Zabkiewicz, C. et al. 2017. Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance. Endocrine-Related Cancer 24 (10), pp.R349-R366. (10.1530/ERC-17-0139)
• Dart, A. D. , Uysal-Onganer, P. and Jiang, W. G. 2017. Prostate-specific PTen deletion in mice activates inflammatory microRNA expression pathways in the epithelium early in hyperplasia development. Oncogenesis 6 (12) 400. (10.1038/s41389-017-0007-5)
• Tong, S. et al., 2017. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma. Scientific Reports 7 (1) 5599. (10.1038/s41598-017-06098-y)
• Liu, Z. et al., 2017. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. Journal of Viral Hepatitis 24 (7), pp.561-572. (10.1111/jvh.12672)
• Lopes-Bastos, B. et al., 2017. Association of breast carcinoma growth with a non-canonical axis of IFNγ/IDO1/TSP1. Oncotarget (10.18632/oncotarget.18781)
• Cui, Y. et al. 2017. MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells. British Journal of Cancer 117 , pp.89-101. (10.1038/bjc.2017.156)
• Jia, S. et al., 2017. Association of Wnt1-inducible signaling pathway protein-1 with the proliferation, migration and invasion in gastric cancer cells. Tumor Biology 39 (6)(10.1177/1010428317699755)
• Koushyar, S. et al. 2017. The prohibitin-repressive interaction with E2F1, is rapidly inhibited by androgen signalling in prostate cancer cells. Oncogenesis 6 , pp.e3333. (10.1038/oncsis.2017.32)
• Liu, Z. et al., 2017. Hey factors at the crossroad of tumorigenesis and clinical therapeutic modulation of Hey for anticancer treatment. Molecular Cancer Therapeutics 16 (5), pp.775-786. (10.1158/1535-7163.MCT-16-0576)
• Ahmad, A. et al., 2017. KIAA1199 promotes migration and invasion by Wnt/β-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer. PLoS ONE 12 (4) e0175058. (10.1371/journal.pone.0175058)
• Ismail, A. F. et al., 2017. PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells. Biochemical Journal 474 (8), pp.1333-1346. (10.1042/BCJ20160875)
• Frugtniet, B. A. et al. 2017. Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion. BMC Cancer 17 (1) 224. (10.1186/s12885-017-3219-3)
• Li, J. et al., 2017. Reduced NOV expression correlates with disease progression in colorectal cancer and is associated with survival, invasion and chemoresistance of cancer cells. Oncotarget (10.18632/oncotarget.15439)
• Kourti, M. , Jiang, W. and Cai, J. 2017. Aspects of carbon monoxide in form of CO-releasing molecules used in cancer treatment: More light on the way. Oxidative Medicine and Cellular Longevity 2017 9326454. (10.1155/2017/9326454)
• Wang, Z. et al., 2017. Poly lactic-co-glycolic acid controlled delivery of Disulfiram to target liver cancer stem-like cells. Nanomedicine: Nanotechnology, Biology and Medicine 13 (2), pp.641-657. (10.1016/j.nano.2016.08.001)
• Feng, Y. et al. 2017. In vitro significance of SOCS-3 and SOCS-4 and potential mechanistic links to wound healing. Scientific Reports 7 (1) 6715. (10.1038/s41598-017-06886-6)
• Gu, Y. et al., 2017. NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway. Oncotarget 8 (5), pp.7753-7765. (10.18632/oncotarget.13949)
• Cai, J. and Jiang, W. 2016. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids. Oncotarget 7 (52), pp.86374-86387. (10.18632/oncotarget.13413)
• Escudero-Esparza, A. et al., 2016. Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer. Oncotarget 7 , pp.76920-76933. (10.18632/oncotarget.12729)
• Ye, L. and Jiang, W. G. 2016. Bone morphogenetic proteins in tumour associated angiogenesis and implication in cancer therapies. Cancer Letters 380 (2), pp.586-597. (10.1016/j.canlet.2015.10.036)
• Meng, R. et al., 2016. NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer. Oncotarget 7 (34), pp.54983-54997. (10.18632/oncotarget.10713)
• Yu, H. et al., 2016. The splice variant Ehm2/1 in breast cancer MCF-7 cells interacted with β--catenin and increased its localization to plasma membrane. RSC Advances 6 (82) 78436. (10.1039/C6RA07975J)
• Hao, C. et al., 2016. Prognostic value of osteopontin splice variant-c expression in breast cancers: a meta-analysis. BioMed Research International 2016 7310694. (10.1155/2016/7310694)
• Liu, R. et al., 2016. Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer. International Journal of Oncology 48 (6), pp.2488-2496. (10.3892/ijo.2016.3462)
• Teagle, A. R. , Birchall, J. C. and Hargest, R. 2016. Gene therapy for pyoderma gangrenosum: optimal transfection conditions and effect of drugs on gene delivery in the HaCaT cell line using cationic liposomes. Skin Pharmacology and Physiology 29 , pp.119-129. (10.1159/000444859)
• Du, G. et al. 2016. The cellular distribution of Na+/H+ exchanger regulatory factor 1 is determined by the PDZ-I domain and regulates the malignant progression of breast cancer. Oncotarget 7 , pp.29440-29453. (10.18632/oncotarget.8751)
• Flamini, V. et al. 2016. Significance and therapeutic implications of endothelial progenitorcells in angiogenic-mediated tumour metastasis. Critical Reviews in Oncology/Hematology 100 , pp.177-189. (10.1016/j.critrevonc.2016.02.010)
• Feng, Y. et al. 2016. Potential roles of suppressor of cytokine signaling in wound healing. Regenerative Medicine 11 (2), pp.193-209. (10.2217/rme.16.4)
• Jia, S. and Cai, J. 2016. Update on biomarkers in development of anti-angiogenic drugs in gastric cancer. Anticancer Research 36 (3), pp.1111-1118.
• Martin, T. A. et al. 2016. Metastasis to bone in human cancer is associated with loss of occludin expression. Anticancer Research 36 (3), pp.1287-1294.
• Owen, S. et al. 2016. Importance of osteoprotegrin and receptor activator of nuclear factor kB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro. International Journal of Oncology 48 (3), pp.919-928. (10.3892/ijo.2016.3339)
• Satherley, L. et al. 2016. Prostate Apoptosis Response-4 (PAR4) suppresses growth and invasion of breast cancer cells and is positively associated with patient survival. Anticancer Research 36 (3), pp.1227-1236.
• Li, J. et al., 2016. Repulsive guidance molecule B inhibits metastasis and is associated with decreased mortality in non-small cell lung cancer. Oncotarget 7 , pp.15678-15689. (10.18632/oncotarget.7463)
• Theodosis-Nobelos, P. et al., 2016. Amides of non-steroidal anti-inflammatory drugs with thiomorpholine can yield hypolipidemic agents with improved anti-inflammatory activity. Biorganic and Medicinal Chemistry Letters 26 (3), pp.910-913. (10.1016/j.bmcl.2015.12.063)
• Salvatore, M. et al., 2016. Hepatoblastoma and microRNA-483 two forms and one outcome. Journal of Genetic Syndromes & Gene Therapy 7 (1) 278. (10.4172/2157-7412.1000278)
• Greensmith, M. , Cho, J. and Hargest, R. 2016. Changes in surgical training opportunities in Britain and South Africa. International Journal of Surgery 25 , pp.76-81. (10.1016/j.ijsu.2015.11.052)
• Koushyar, S. , Jiang, W. G. and Dart, D. A. 2015. Unveiling the potential of prohibitin in cancer. Cancer Letters 369 (2), pp.316-322. (10.1016/j.canlet.2015.09.012)
• Block, K. I. et al., 2015. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology 35 , pp.S276-S304. (10.1016/j.semcancer.2015.09.007)
• Bradbury, R. , Jiang, W. G. and Cui, Y. 2015. The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers. Biomarkers in Medicine 9 (12), pp.1353-1370. (10.2217/bmm.15.94)
• Collins, R. J. et al. 2015. EPLIN: a fundamental actin regulator in cancer metastasis?. Cancer and Metastasis Reviews 34 (4), pp.753-764. (10.1007/s10555-015-9595-8)
• Jiang, W. G. et al. 2015. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Seminars in Cancer Biology 35 , pp.S244-S275. (10.1016/j.semcancer.2015.03.008)
• Soliman, F. , Sturgeon, G. and Hargest, R. 2015. Revisiting an ancient treatment for transphincteric fistula-in-ano 'There is nothing new under the sun' Ecclesiastes 1v9. Journal of the Royal Society of Medicine 108 (12), pp.482-489. (10.1177/0141076815588322)
• Theodosis-Nobelos, P. et al., 2015. Esters of some non-steroidal anti-inflammatory drugs with cinnamyl alcohol are potent lipoxygenase inhibitors with enhanced anti-inflammatory activity. Biorganic & Medicinal Chemistry Letters 25 (22), pp.5028-5031. (10.1016/j.bmcl.2015.10.036)
• Li, J. et al. 2015. MTA1 is up-regulated in colorectal cancer and is inversely correlated with lymphatic metastasis. Cancer Genomics and Proteomics 12 (6), pp.339-346.
• Englund, E. et al., 2015. The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients. BMC Cancer 15 737. (10.1186/s12885-015-1734-7)
• Ma, Q. et al., 2015. MAGI3 negatively regulates Wnt/β-catenin signaling and suppresses malignant phenotypes of glioma cells. Oncotarget 6 (34), pp.35851-35865. (10.18632/oncotarget.5323)
• Liu, R. et al., 2015. Metastasis suppressor 1 expression in human ovarian cancer: the impact on cellular migration and metastasis. International Journal of Oncology 47 (4), pp.1429-1439. (10.3892/ijo.2015.3121)
• Ji, J. et al., 2015. WISP-2 in human gastric cancer and its potential metastatic suppressor role in gastric cancer cells mediated by JNK and PLC-γ pathways. British Journal of Cancer 113 (6), pp.921-933. (10.1038/bjc.2015.285)
• Jiang, W. G. et al. 2015. 3117 Effects of YangZheng XiaoJi on the migration and growth of lung cancer cells, by targeting the Hepatocyte Growth Factor Receptor-Epidermal Growth Factor Receptor (HGFR-EGFR) transactivation. European Journal of Cancer 51 (Supp 1), pp.S642. (10.1016/S0959-8049(16)31758-0)
• Jiang, W. G. et al. 2015. YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells. Journal of Translational Medicine 13 280. (10.1186/s12967-015-0639-1)
• Brooke, G. N. et al., 2015. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells. Molecular & Cellular Proteomics 14 (5), pp.1201-1216. (10.1074/mcp.M113.036764)
• Webber, J. P. et al. 2015. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 34 (3), pp.290-302. (10.1038/onc.2013.560)
• Martin, T. A. 2014. The role of tight junctions in cancer metastasis. Seminars in Cell and Developmental Biology 36 , pp.224-231. (10.1016/j.semcdb.2014.09.008)
• Fletcher, C. E. , Dart, D. and Bevan, C. L. 2014. Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers. Endocrine-Related Cancer 21 (5), pp.R409-R429. (10.1530/ERC-14-0208)
• Ye, L. et al. 2014. Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour-related angiogenesis. International Journal of Oncology 45 (4), pp.1565-1573. (10.3892/ijo.2014.2533)
• Sanders, A. J. et al. 2014. Tumour angiogenesis and repulsive guidance molecule b: A role in HGF- and BMP-7-mediated angiogenesis. International Journal of Oncology 45 (3), pp.1304-1312. (10.3892/ijo.2014.2508)
• Martin, T. A. , Mason, M. D. and Jiang, W. G. 2014. HGF and the regulation of tight junctions in human prostate cancer cells. Oncology Reports 32 (1), pp.213-224. (10.3892/or.2014.3219)
• Teagle, A. and Hargest, R. 2014. Management of pyoderma gangrenosum. Journal of the Royal Society of Medicine 107 (6), pp.228-236. (10.1177/0141076814534407)
• Chen, Z. et al., 2014. Discovery of structure-based small molecular inhibitor of alpha B-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo. Breast Cancer Research and Treatment 145 (1), pp.45-59. (10.1007/s10549-014-2940-8)
• Jordan, N. J. et al. 2014. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Research 16 (1), pp.-. R12. (10.1186/bcr3604)
• Jia, Y. et al., 2014. Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. British Journal of Cancer 110 (2), pp.421-429. (10.1038/bjc.2013.712)
• Power, K. et al., 2014. A case-control study of risk factors for wound infection in a colorectal unit. Annals of the Royal College of Surgeons of England 96 (1), pp.37-40. (10.1308/003588414X13824511650137)
• Martin, T. A. and Jiang, W. G. 2014. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma. Oncology Reports 31 (1), pp.262-272. (10.3892/or.2013.2813)
• Ji, K. et al. 2014. Implication of metastasis suppressor gene, Kiss-1 and its receptor Kiss-1R in colorectal cancer. BMC Cancer 14 723. (10.1186/1471-2407-14-723)
• Martin, T. A. et al. 2013. The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis. PLoS ONE 8 (12) e82696. (10.1371/journal.pone.0082696)
• Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
• Dart, D. A. et al. 2013. Visualising androgen receptor activity in male and female mice. PLoS ONE 8 (8) e71694. (10.1371/journal.pone.0071694)
• Sun, P. et al. 2013. Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer. Journal of Cancer Research and Clinical Oncology 139 (7), pp.1129-1139. (10.1007/s00432-013-1421-5)
• Frewer, N. et al. 2013. Potential implication of IL-24 in lymphangiogenesis of human breast cancer. International Journal of Molecular Medicine 31 (5), pp.1097-1104. (10.3892/ijmm.2013.1319)
• Chong, R. et al. 2013. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. Journal of Controlled Release 166 (3), pp.211-219. (10.1016/j.jconrel.2012.12.030)
• Frewer, K. et al. 2013. A role for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics and Proteomics 10 (4), pp.187-196.
• Blake, P. et al., 2012. Large bowel obstruction due to colorectal carcinoma can be safely treated by colonic stent insertion - case series from a UK district general hospital. Colorectal Disease 14 (12), pp.1489-1492. (10.1111/j.1463-1318.2012.03035.x)
• Hiscox, S. E. et al. 2012. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 12 458. (10.1186/1471-2407-12-458)
• Dart, D. A. et al. 2012. Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene 31 (43), pp.4588-4598. (10.1038/onc.2011.591)
• Ji, K. et al. 2012. Expression of signal-induced proliferation-associated gene 1 (SIPA1), a rapGTPase-activating protein, is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. Cancer Genomics and Proteomics 9 (5), pp.321-327.
• Fletcher, C. E. et al., 2012. Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer. Human Molecular Genetics 21 (14), pp.3112-3127. (10.1093/hmg/dds139)
• Cai, J. et al. 2012. ?-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Molecular Medicine 4 (9), pp.980-991. (10.1002/emmm.201101084)
• Brooke, G. . N. et al., 2011. FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Research 71 (3), pp.914-924. (10.1158/0008-5472.CAN-10-0874)
• Zimbwa, T. A. et al. 2010. An unusual complication of colitis. Gut 59 (3), pp.364-364. (10.1136/gut.2009.179689)
• Pearce, L. et al. 2010. Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica 95 (3), pp.514-517. (10.3324/haematol.2009.014381)
• Lane, J. , Martin, T. A. and Jiang, W. G. 2010. Targeting RhoC by way of ribozyme trangene in human breast cancer cells and its impact on cancer invasion. World Journal of Oncology 1 (1), pp.7-13. (10.4021/wjon2010.01.1202)
• Ye, L. et al. 2010. Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Science 101 (10), pp.2137-2144. (10.1111/j.1349-7006.2010.01648.x)
• Ye, L. , Kynaston, H. and Jiang, W. G. 2009. Bone Morphogenetic Protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. The Journal of Urology 181 (6), pp.2749-2759. (10.1016/j.juro.2009.01.098)
• Hiscox, S. E. et al. 2009. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 115 (1), pp.57-67. (10.1007/s10549-008-0058-6)
• Lane, J. et al. 2008. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. International Journal of Oncology 33 (3), pp.585-593. (10.3892/ijo_00000044)
• Morgan, L. D. , Nicholson, R. and Hiscox, S. 2008. Src as a therapeutic target in breast cancer. Endocrine‚ Metabolic & Immune Disorders - Drug Targets 8 (4), pp.273-278. (10.2174/187153008786848295)
• Ye, L. , Kynaston, H. and Jiang, W. G. 2008. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Molecular Cancer Research 6 (10), pp.1594-1606. (10.1158/1541-7786.MCR-08-0171)
• Morgan, L. D. 2007. Elevated Src kinase activity accompanies endocrine-resistance in breast cancer and promotes an aggressive cell phenotype. PhD Thesis , Cardiff University.
• Hiscox, S. E. et al. 2006. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of [beta]-catenin phosphorylation. International journal of cancer 118 (2), pp.290-301. (10.1002/ijc.21355)